Study of Pembrolizumab versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Trial Identifier:	3475-033
Sponsor:	MSD
Start Date:	September 2016
Primary Completion Date:	September 2019
Study Completion Date:	October 2022
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Results Plain Language Summary - English
	Results Plain Language Summary - LA Spanish

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.